FDA Awards Fast-Track Voucher for Rare Kids' Blood Disorder Drug
Published Date: 2/23/2026
Notice
Summary
The FDA just gave a special fast-track prize called a Priority Review Voucher to Fondazione Telethon ETS for their rare disease treatment, WASKYRA, approved in December 2025. This medicine helps kids and adults with Wiskott-Aldrich Syndrome who need a stem cell transplant but can’t find a perfect donor. This voucher speeds up future drug reviews and can be sold, saving time and money for drug developers.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
WASKYRA Approved for WAS Patients
WASKYRA (etuvetidigene autotemcel) was approved on December 9, 2025, for pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable HLA‑matched related stem cell donor is available. If you are in that patient group, this approval makes the treatment an approved option.
FDA Issues Rare Disease Priority Voucher
The FDA issued a Priority Review Voucher to Fondazione Telethon ETS for WASKYRA after its approval on December 9, 2025. The notice says this voucher speeds up future drug reviews and can be sold, which can save time and money for drug developers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in